COMMUNIQUÉS West-GlobeNewswire

Idorsia financial results for the first nine months of 2018
23/10/2018
Allschwil, Switzerland - 23 October 2018 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2018. Jean-Paul Clozel, MD and Chief Executive Officer, commented: "Idorsia continues [...]
Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer
23/10/2018
As Chief Commercial Officer Simon Jose will join the Idorsia Executive Committee Simon's first priority will be to establish a commercial organization Allschwil, Switzerland - October 23, 2018 Idorsia Ltd (SIX: IDIA) [...]
Innate Pharma strengthens and expands its oncology development collaboration with AstraZeneca
23/10/2018
Innate Pharma acquires US and EU rights to commercialize Lumoxiti to become a fully-integrated oncology-focused biotech AstraZeneca obtains full oncology rights to monalizumab AstraZeneca gains access to Innate Pharma's [...]
Innate Pharma renforce et étend sa collaboration de développement en oncologie avec AstraZeneca
23/10/2018
Innate Pharma fait l'acquisition des droits de commercialisation de l'anti-cancéreux Lumoxiti aux Etats-Unis et en Europe, devenant une société de biotechnologies intégrée AstraZeneca acquiert l'intégralité des droits [...]
MDxHealth Provides Business Update for the first nine months of 2018
23/10/2018
NEWS RELEASE REGULATED INFORMATION INTERIM TRADING UPDATE Product and Service revenue up 29% year-on-year IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, October 23, 2018 - MDxHealth SA ("MDxHealth, or the "Company"), ( [...]
MDxHealth (R): MDxHealth publie son rapport d'activités intermédiaire relatif aux neuf premiers mois de 2018
23/10/2018
COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES RAPPORT D'ACTIVITÉS INTERMÉDIAIRE Les revenus liés aux produits et services en hausse de 29 % par rapport à l'année précédente IRVINE, CA, et HERSTAL, BELGIQUE - 07h00 CEST [...]
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
23/10/2018
BRUSSELS, Belgium and CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Today UCB (Euronext Brussels: UCB) and Biogen Inc . (Nasdaq: BIIB) announced top-line results from a Phase 2b study evaluating the safety and [...]
IntelGenx Completes US$12 Million Equity Offering
23/10/2018
SAINT LAURENT, Quebec, Oct. 22, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “ Company ” or “ IntelGenx ”) is pleased to announce that it has closed its offering (the “ Offering [...]
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed
23/10/2018
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported significant reductions in [...]
Chembio Announces Proposed Public Offering of Common Stock
22/10/2018
MEDFORD, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio” or the “Company”), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it [...]
INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5
22/10/2018
PHOENIX, Oct. 22, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced [...]
National Research Corporation to Broadcast its 2018 Third Quarter Conference Call Live on the Internet
22/10/2018
Lincoln, Nebraska, Oct. 22, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ/:NRC) today announced that it will provide an online web simulcast of its 2018 third quarter earnings conference call on [...]
ContraFect to Participate in World Antimicrobial Resistance Congress 2018
22/10/2018
YONKERS, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]
MacroGenics Announces Participation in Three Investor Conferences
22/10/2018
ROCKVILLE, MD, Oct. 22, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
NanoVibronix to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
22/10/2018
ELMSFORD, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- NanoVibronix, Inc., (NASDAQ: NAOV) , a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, [...]
Chembio Reports Preliminary Third Quarter 2018 Revenue
22/10/2018
Signs Definitive Agreement to Acquire opTricon GmbH MEDFORD, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio” or the “Company”), a leading point-of-care diagnostics company [...]
Osmotica Pharmaceuticals plc Announces Closing of Initial Public Offering
22/10/2018
BRIDGEWATER, N.J., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, today announced the closing of its initial public offering of 7,647,500 ordinary shares at [...]
CLEARSIDE, XIPERE™ and PEACHTREE to be Front and Center at AAO 2018
22/10/2018
ALPHARETTA, Ga., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Harvard Bioscience Names Kam Unninayar as Chief Financial Officer
22/10/2018
Seasoned Financial Executive With More Than a Decade in Global Life Science Instrumentation, Will Begin on November 26 HOLLISTON, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “ [...]

Pages